Federated Hermes, Inc. Galecto, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$1.06 - $58.5 $42,400 - $2.34 Million	40,000 Added 66.67%	100,000 $114,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $60.0 $31,800 - $1.2 Million	20,000 Added 50.0%	60,000 $113,000
Q2 2022 Aug 15, 2022	BUY	$1.22 - $2.74 $17,080 - $38,360	14,000 Added 53.85%	40,000 $69,000
Q4 2021 Feb 14, 2022	BUY	$2.3 - $3.58 $13,799 - $21,480	6,000 Added 30.0%	26,000 $79,000
Q3 2021 Nov 15, 2021	BUY	$3.59 - $5.0 $28,720 - $40,000	8,000 Added 66.67%	20,000 $72,000
Q2 2021 Aug 16, 2021	SELL	$4.63 - $8.0 $37,040 - $64,000	-8,000 Reduced 40.0%	12,000 $61,000
Q4 2020 Feb 12, 2021	BUY	$12.51 - $16.84 $250,200 - $336,800	20,000 New	20,000 $250,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $119M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.